297 results about "Influenza Viruses Type A" patented technology

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the membrane of a virosome or virus-like particles. Immunogenicity and the breadth of cross protection efficacy are significantly enhanced using multiple copies of the influenza M2 protein as a membrane bound tetramer and/or in combination with a membrane bound adjuvant. A method for vaccinating a subject for influenza A has also been developed that results in broad and improved cross-protection against multiple subtypes of influenza A virus.

A method of immunoassay of H5 subtype influenza A virus by which the virus can be accurately assayed even in cases where a certain level of mutation has occurred in the H5 subtype influenza A virus, and a kit therefor, and a novel anti-H5 subtype influenza A virus monoclonal antibody which can be used for the immunoassay are disclosed. The antibody or an antigen-binding fragment thereof of the present invention undergoes antigen-antibody reaction with hemagglutinin of H5 subtype influenza A virus, and the corresponding epitope of the antibody or an antigen-binding fragment thereof is located in a region other than the receptor subdomain (excluding C-terminal region thereof consisting of 11 amino acids), which antibody or an antigen-binding fragment thereof does not have neutralizing activity against the influenza A virus.

Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.

The invention belongs to the field of functional fiber materials, and discloses a traditional Chinese medicine compound anti-coronavirus and anti-flu-virus composite antibacterial multifunctional fiber. The fiber comprises traditional Chinese medicine antiviral particles, inorganic antibacterial particles, health-care functional particles and a fiber matrix. The traditional Chinese medicine antiviral particles are silicon dioxide aerogel microspheres loaded with traditional Chinese medicine antiviral components, and the traditional Chinese medicine antiviral components comprise radix isatidis,dandelions, honeysuckle flowers, wild chrysanthemum flowers, folium isatidis, herba andrographitis, citrus chachiensis hortorum, ageratum and mint extracts. According to the traditional Chinese medicine compound anti-coronavirus and anti-flu-virus composite antibacterial multifunctional fiber, the silicon dioxide aerogel microspheres are innovatively adopted as carriers of the traditional Chinesemedicine antiviral components and are introduced into fiber materials, so that the traditional Chinese medicine antiviral functional components can be protected from being damaged in the fiber forming process, and a good antiviral effect is achieved. The antiviral activity rate of the fiber product obtained through testing against coronaviruses Hcov-229E and influenza A viruses H1N1 can reach 99%or above.

The invention provides a fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR) kit for detecting an influenza A virus subtype H7N9. The fluorescent quantitative RT-PCR kit can be used for detection of influenza A viruses and the influenza A virus subtype H7N9. The fluorescent quantitative RT-PCR kit comprises a quantitative RT-PCR reaction solution, an enzyme mixed liquor, a primer and probe mixed liquor, standard substances of influenza A viruses, H7, N9 and RNaseP, positive reference substances of influenza A viruses, H7, N9 and RNaseP), and negative reference substances. Specific primers and probes are designed according to conserved sequences of influenza A viruses, H7 and N9. The RNaseP primers and probes are used as internal references. Through the one-step quadruple real-time fluorescent RT-PCR technology, the influenza A virus and the influenza A virus subtype H7N9 in the sample can be fast and accurately detected. The fluorescent quantitative RT-PCR kit has a reasonable design, very high singularity, sensitivity and repeatability, can be used for laboratory emergency diagnosis and fast screening of an epidemic disease caused by the influenza A virus subtype H7N9, and for an epidemiology study on the influenza A virus and the influenza A virus subtype H7N9 causing fever and respiratory tract syndrome.

The invention provides a kit for nucleic acid combined detection of the influenza virus A, the influenza virus B and the respiratory syncytial virus. The kit comprises RT-PCR reaction liquid, an RT-PCR enzyme mixture, a respiratory virus primer probe, internal reference, negative contrast, clinical positive contrast and strong positive contrast. The one-step RT-PCR reaction can be directly conducted on the well-extracted respiratory virus nucleic acid, the influenza virus A, the influenza virus B and the respiratory syncytial virus in a sample can be detected in a classified and qualitative mode, the gene of the internal reference serves as the internal contrast, and contamination is prevented through UNG enzymes. The kit is simple in one-step amplification method, short in procedure, easy and convenient to operate, capable of preventing contamination, high in detection result specificity, high in sensitivity, clear in result, high in credibility, and capable of being used for qualitatively authenticating and detecting the influenza virus A, the influenza virus B and the respiratory syncytial virus in a human nose pharynx-mop sample.

The invention discloses a folium isatidis cellulose fiber having antiviral, antibacterial and skin-care functions and a preparation method thereof. The folium isatidis cellulose fiber contains, by weight, 2.0-8.0 parts of folium isatidis extract, 2.0-8.0 parts of sodium caseinate, 2-30 parts of porous starch and 2-50 parts of protein. The preparation method includes the following steps that 1, preparation of folium isatidis extract-sodium caseinate compound microcapsules, 2 preparation of a blended spinning stock solution and 3 spinning and post-processing. Compared with conventional viscose fibers, the influenza A virus inactivation rate of the fiber is 82.0% or above, the herpes virus inactivation rate is 84.0% or above, a bacteriostatic activity value is greater than or equal to 2.0, a bactericidal activity value is greater than or equal to 0.2, a variety of amino acids and trace elements are contained in the fiber, the fiber has good skin-care and health-care functions, the physical index of the product can meet the requirements of GB/T14463-2008 viscose staple fiber first-grade products, and the fiber has good wearability and textile processing performance.

The invention discloses a detection method and a detection kit of influenza A virus, H1N1 and H3N2 subtype influenza virus, which has the advantages of specificity, sensitivity, good repeatability, fastness and low cost. A specific primer and a TaqMan probe are designed through sequence alignment for searching a highly conserved area according to a North American variant strain M gene of Influenza A Viruse(H1N1)virus in 2009, an HA gene sequence and the HA gene sequence of Influenza A Viruse(H3N2) epidemic strain, which are published in GeneBank; key reagents such as the probe, the primer and positive control (to structure the influenza A virus, the H1N1 and the H3N2 subtype influenza virus gene recombination clone plasmid) in the detection method are developed; and the influenza A virus, H1N1 and H3N2 subtype influenza virus real-time fluorescence RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection method is established through the optimization of various reaction conditions and the tests on the specificity, the sensitivity and the repeatability. The detection method can be used for simultaneously and specifically detecting the influenza A virus, the H1N1 subtype influenza virus and the H3N2 subtype influenza virus in one test.

The invention relates to the field of medical detection, in particular to a primer probe combination for detecting six respiratory viruses, a kit and application. According to the kit provided by theinvention, a method of combining isothermal amplification and a micro-fluidic chip is adopted; the kit can accurately detect novel coronavirus (2019-nCoV) S and N target genes and influenza A virus, novel influenza A H1N1 virus (2009), influenza A H3N2 virus, influenza B virus and respiratory syncytial virus at the same time, and the purpose of distinguishing the novel coronavirus from common influenza virus is achieved. The kit disclosed by the invention has the advantages of multiple detection indexes, simplicity and convenience in operation, short detection time and the like, six virus indexes can be simultaneously detected by one-time sample adding, the time from sample treatment to report is within 1.5 hours, and the kit is more time-saving and labor-saving than qPCR method.

The invention relates to probes and assays which are used for the simultaneous detection, in a single assay sample, of a plurality of nucleic acid sequences of viruses that cause respiratory infections in humans, selected from among influenza virus type A, influenza virus type B, influenza virus type C, human respiratory syncytial virus type A, human respiratory syncytial virus type B, human adenovirus, human parainfluenza virus type 1, human parainfluenza virus type 2, human parainfluenza virus type 3, human parainfluenza virus types 4A and 4B, enterovirus, rhinovirus, human coronavirus type 229E, human coronavirus type OC43, coronavirus that causes severe acute respiratory syndrome (SARS), human metapneumovirus and combinations thereof.

The present disclosure relates to a real-time fluorescence multiplex PCR primer probe for seven common respiratory system influenza virus pathogens and a kit. Seven influenza viruses are influenza A virus, influenza B virus, parainfluenza virus type I, parainfluenza virus type II, parainfluenza virus type III, respiratory syncytial virus and adenovirus. The present disclosure also provides a kit for multiplex fluorescence quantitative PCR detection of the seven influenza viruses, and the kit includes the primer probe set. The kit significantly improves the sensitivity, specificity, and simplicity of detection of the common respiratory system pathogens.

The invention discloses the application of a traditional Chinese medical composition in the preparation of a medicament for resisting influenza A H1N1 influenza viruses. The traditional Chinese medical composition is prepared from the medical materials of forsythia, honeysuckle, ephedra, bitter almond, and the like, has broad-spectrum antiviral action, can effectively kill the viruses, reduce fever and diminish inflammation. Proved by experiments, the traditional Chinese medical composition can accurately resist the influenza A H1n1 influenza viruses.

The invention belongs to the field of molecular biological detection, and relates to a multiple RT-RPA primer combination for influenza A virus detecting and H1 and H3 typing and application thereof.The multiple RT-RPA primer combination for influenza A virus detecting and H1 and H3 typing comprises an RT-RPA primer for detecting an influenza A virus Matrix gene, an H1 subtype HA gene and an H3 subtype HA gene, and the sequences are sequentially shown in SEQ ID NO.1-NO.6. The multiple RT-RPA primer combination can be used for detecting an influenza A virus and verifying H1 and H3 subtypes. According to the multiple RT-RPA primer combination, a multiple RT-RPA method is adopted for detecting the influenza A virus and verifying the H1 and H3 subtypes for the first time, and the combinationis short in consumed time, high in sensitivity and specificity and capable of being quickly and effectively used for influenza A virus detecting and H1 and H3 typing.

The invention discloses a radix wikstroemae extractive and a preparation method and an application thereof. The radix wikstroemae extractive comprises 4'-methoxyl daphne odora E and thymol. The preparation method of the radix wikstroemae extractive has the following steps: dried root and root bark of the radix wikstroemae is extracted by ethanol water, then the extractive is enriched by macroporous absorption resin column or polyamide column. The extractive can be used for preparing medicine or health-care products for resisting respiratory syncytial virus, parainfluenza type III virus and influenza A virus.

The invention provides an ordinary/chimeric virus-like particle of an H7 subtype influenza virus H7N9, a preparation method and application of the ordinary/chimeric virus-like particle, and a vaccine,and belongs to the technical field of bioengineering and viral vaccines. The ordinary/chimeric virus-like particle of the H7 subtype influenza virus is used for preparing the vaccine, and accordingly, the safety problems of existing vaccines are well solved; the obtained vaccine has high antibody valence and obvious effect; the ordinary/chimeric virus-like particle has wide application range andhigh actual application value.

The present invention discloses hybridoma cell strain whose conservative number is CGMCC 0987, anti-influenza A virus nucleoprotein monoclonal antibody produced by said hybridoma cell strain and influenza A virus colloidal gold fast detection testing paper containing said monoclonal antibody. Said detection testing paper can be used for quickly detecting influenza A virus, its specificity, sensitivity and accuracy are high, and its storage and transportation are convenient.

The invention discloses a novel coronavirus antigen and influenza virus antigen combined detection reagent strip which comprises a bottom plate. A sample pad, a gold-labeled pad, a nitrocellulose membrane and absorbent paper are sequentially pasted on the bottom plate, and the surface of the nitrocellulose membrane is sequentially coated with an anti-novel coronavirus antibody, an anti-influenza Avirus antibody and an anti-influenza B virus antibody. A rabbit anti-mouse IgG antibody coats the end close to the absorbent paper. A colloidal gold labeled anti-novel coronavirus antibody, an anti-influenza A virus antibody and an anti-influenza B virus antibody are sprayed on the gold-labeled pad. The binding protein A/G is marked on the surface of the colloidal gold, the protein A/G is specifically bound with the Fc end of the antibody, so that the ideal conformation of Fab end abduction is constructed, and meanwhile, the binding of the protein A/G with the Fc can reduce the false positiveinterference of rheumatoid factors on a detection structure. The reagent strip can simultaneously realize qualitative detection of the novel coronavirus antigen and the influenza antigen in one test,and is convenient to use, good in sensitivity, high in specificity and short in detection time.

There are provided inter alia metalloenzyme inhibitors, such as inhibitors of influenza A RNA dependent RNA polymerase PA subunit endonuclease, and methods of synthesis and use of the same.

The invention relates to a colloidal gold diagnostic test paper for influenza A virus and a preparation method thereof for effectively solving such problems in the prior art as low testing sensitivity, low accuracy rate, and high missing detection rate. According to the technical scheme, the test paper comprises a test paper shell and a test paper strip, wherein the test paper strip is arranged in the test paper shell, the test paper strip is composed of a sample pad, a colloidal gold pad, a reaction membrane and a backing, the reaction membrane is adhered to the middle part of the backing, a detection line and a control line are sprayed on the reaction membrane, a water absorption pad is adhered to the tail part of the backing, one end of the water absorption pad is pressed on one end of the reaction membrane, the colloidal gold pad is adhered to the upper part of the backing, one end of the colloidal gold pad is pressed on the other end of the reaction membrane, the sample pad is adhered to the head part of the backing, close to one end of the colloidal gold pad, and one end of the sample pad is pressed on the other end of the colloidal gold pad. The colloidal gold diagnostic test paper for influenza A virus has the advantages of good testing sensitivity, high accuracy rate and low missing detection rate, and is innovation in the field of influenza A virus test paper.

The invention provides a double fluorescent quantitative PCR detection kit of type A H1N1/type A influenza virus nucleic acid, comprising RNase inhibitor, RT-PCR reaction solution, enzyme mixed solution, type A H1N1/type A influenza virus double reaction solution , a positive control and a negative control, wherein said A/H1N1/influenza A double reaction solution includes the following components: Component (1): a pair of primers for detecting A/H1N1 influenza virus and a primer for detecting A Type H1N1 influenza virus probe composition; component (2): composed of a pair of primers for detecting influenza A virus and a probe for detecting influenza A virus; said enzyme mixture includes Taq enzyme and reverse transcriptase . The invention can detect influenza A H1N1 and influenza A virus at the same time, and solves the problem that the existing products can only detect one type of influenza virus in one tube reaction. The invention has the advantages of simple operation, strong repeatability, rapid and objective detection results, etc., and has great application prospects in the field of in vitro diagnosis of influenza virus.

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.